Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Joanne Salageanu"'
Autor:
Joseph, Piscitelli, Joseph, Chen, Robert R, LaBadie, Joanne, Salageanu, Chin-Hee, Chung, Weiwei, Tan
Publikováno v:
Clinical Drug Investigation. 42:221-235
Dacomitinib is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations. To evaluate the effect of hepatic impairment on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ad86a1a5e81b416a4a9f48c18979703
https://doi.org/10.1007/s40261-022-01125-x
https://doi.org/10.1007/s40261-022-01125-x
Autor:
Tong Zhu, Sylvester Pawlak, Sima S. Toussi, Frances Hackman, Kimberly Thompson, Wei Song, Joanne Salageanu, Erica Winter, Haihong Shi, Jennifer Winton, Michael Binks
Publikováno v:
Clinical pharmacology in drug developmentReferences. 11(12)
Studies on targeted antivirals for treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of the ongoing pandemic, are limited. PF-07304814 (lufotrelvir) is the phosphate prodrug of PF-00835231, a protease inhibitor targ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e93420f13b1ffa2c5f2aad799f91e80
https://pubmed.ncbi.nlm.nih.gov/36285536
https://pubmed.ncbi.nlm.nih.gov/36285536
Publikováno v:
Clinical Pharmacology in Drug Development
This phase I open‐label trial (NCT03627754) assessed glasdegib pharmacokinetics and safety in otherwise healthy participants with moderate (Child‐Pugh B) or severe (Child‐Pugh C) hepatic impairment. Participants with hepatic impairment and age/
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8622b7930e3df3ee8ebbdc4939c1920
https://pubmed.ncbi.nlm.nih.gov/33356019
https://pubmed.ncbi.nlm.nih.gov/33356019
Autor:
Anna Plotka, Khurshid Mridha, Beth Sullivan, Joanne Salageanu, Daniel Baltrukonis, Ellen Q. Wang, Robert Frederich
Publikováno v:
Clinical Pharmacology in Drug Development. 8:40-48
The pharmacokinetics (PK) and pharmacodynamics (PD) of bococizumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, were compared following a single 150-mg subcutaneous dose administered to healthy subjects (n = 156-158/arm) via: (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80b9f3a965d04265e8cf962d022f8fde
https://doi.org/10.1002/cpdd.454
https://doi.org/10.1002/cpdd.454
Publikováno v:
Clinical Drug Investigation. 35:267-274
ALO-02 capsules, intended to deter abuse, contain pellets of extended-release oxycodone hydrochloride (HCl), an opioid agonist, surrounding sequestered naltrexone HCl, an opioid antagonist. The objective of this study was to determine the effects of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34ea48645bb24a8c04f64aaa08ec7991
https://doi.org/10.1007/s40261-015-0278-6
https://doi.org/10.1007/s40261-015-0278-6
Autor:
Michael J. Lamson, Joanne Salageanu, Kyle Matschke, Bimal Malhotra, Kuan Gandelman, Candace Bramson
Publikováno v:
Clinical Pharmacology in Drug Development. 4:370-376
WHAT IS KNOWN AND OBJECTIVE ALO-02 is being developed as an abuse-deterrent formulation of extended-release oxycodone hydrochloride with naltrexone hydrochloride sequestered in the core of pellets contained in capsules. The primary objective of this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b8dafabfc30dc17d21b44dad09ca608a
https://doi.org/10.1002/cpdd.177
https://doi.org/10.1002/cpdd.177
Autor:
Kyle Matschke, Michael J. Lamson, Joanne Salageanu, Candace Bramson, Kuan Gandelman, Bimal Malhotra
Publikováno v:
Clinical Pharmacology in Drug Development. 4:361-369
ALO-02 capsules (ALO-02) contain pellets that consist of extended-release oxycodone that surrounds sequestered naltrexone. The primary objective was to characterize the pharmacokinetics (PK) of oxycodone following single- and multiple-dose oral admin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9d323f01a920a14fa772d91f3081bf8d
https://doi.org/10.1002/cpdd.179
https://doi.org/10.1002/cpdd.179
Publikováno v:
Cardiovascular Therapeutics. 35:e12278
SummaryAim To characterize the single-dose pharmacokinetics (PK) and pharmacodynamics (PD) of bococizumab, a monoclonal antibody inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9), administered subcutaneously (s.c.) to the abdomen, thig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d6b33ea3106e17c3fda875a31f005e5
https://doi.org/10.1111/1755-5922.12278
https://doi.org/10.1111/1755-5922.12278
Autor:
Kuan, Gandelman, Michael, Lamson, Joanne, Salageanu, Candace, Bramson, Kyle, Matschke, Bimal, Malhotra
Publikováno v:
Clinical pharmacology in drug development. 4(5)
ALO-02 is being developed as an abuse-deterrent formulation of extended-release oxycodone hydrochloride with naltrexone hydrochloride sequestered in the core of pellets contained in capsules. The primary objective of this study was to assess the effe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7b2594d72467f0f034452693b5bfb7ab
https://pubmed.ncbi.nlm.nih.gov/27137146
https://pubmed.ncbi.nlm.nih.gov/27137146
Publikováno v:
Journal of Bioequivalence & Bioavailability.
Background: ALO-02, an opioid formulation intended to deter abuse, comprising capsules filled with pellets of extended-release oxycodone hydrochloride, an opioid, surrounding sequestered naltrexone hydrochloride, an opioid antagonist. This study comp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73ae54f572be41b2349b3991dd4a4876
https://doi.org/10.4172/jbb.1000202
https://doi.org/10.4172/jbb.1000202